Summit Therapeutics SMMT
NASDAQ SMMT
$16.40 +0.92 (+5.94%)
As of: Sep 29, 2026 · 3:59 PM EDT

Summit Therapeutics (SMMT) Gains from Sales and Divestitures (2019 - 2023)

Updated

Summit Therapeutics (SMMT) posted Gains from Sales and Divestitures of -$2,000 for Q4 2023.

Analysis

Summit Therapeutics (SMMT) Gains from Sales and Divestitures (2019 - 2023) Analysis & Trends

For FY2023, Summit Therapeutics' Gains from Sales and Divestitures came in at $109,000.

  • In prior years, Summit Therapeutics' Gains from Sales and Divestitures was -$2,000 in FY2020 and -$13,000 in FY2019.
  • Quarterly Gains from Sales and Divestitures has run from a low of -$11,000 in Q3 2023 to a high of $20,000 in Q4 2019 over five years.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 655.56 Bn 574.09 Bn 17.26 Bn
2 AbbVie 470.94 Bn 444.10 Bn 12.70 Bn
3 Merck 367.14 Bn 321.57 Bn 12.21 Bn
4 Novartis Ag 280.33 Bn 236.20 Bn 11.24 Bn
5 Astrazeneca 257.78 Bn 231.34 Bn 12.86 Bn
6 Amgen 226.04 Bn 181.44 Bn 7.24 Bn
7 Gilead Sciences 188.89 Bn 163.01 Bn 6.22 Bn
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn
9 Vertex Pharmaceuticals 133.68 Bn 105.69 Bn 2.84 Bn
10 Summit Therapeutics 12.28 Bn 10.04 Bn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2023 -2,000.00
Sep 30, 2023 -11,000.00
Dec 31, 2020 -2,000.00
Dec 31, 2019 20,000.00
API Access

Summit Therapeutics Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=SMMT&period=max&api_key=YOUR_API_KEY